X PAPER / Full editionIssue 010 · October 15, 2026

Biomedicine / 报道

Roche licenses ALK7 candidate; $1.16 billion is conditional

Source author: ChineseWSJ · @ChineseWSJ
Source posted:
Written and edited by

Rona Therapeutics announced October 13 an exclusive worldwide license to Roche for an investigational ALK7-targeting RNA-interference therapy. Its extrahepatic delivery approach targets fat-cell biology, distinct from appetite-focused incretin therapies.

Upfront and near-term milestones total up to 100 million dollars. A further 1.06 billion is conditional on development, regulatory and commercial milestones, with tiered royalties on global net sales. The headline 1.16 billion is not cash already paid.

Reducing visceral fat while preserving lean mass is the company’s development rationale, not demonstrated patient benefit in this announcement. No human efficacy data were supplied. The October 14 post follows an October 13 agreement.

Sources and further reading

edited

Selected through a verified followed account: @ChineseWSJ.